PDSB vs. ENGN, GNFT, CRGX, ACIU, HRTX, OGI, AARD, IPHA, LYEL, and CGTX
Should you be buying PDS Biotechnology stock or one of its competitors? The main competitors of PDS Biotechnology include enGene (ENGN), GENFIT (GNFT), CARGO Therapeutics (CRGX), AC Immune (ACIU), Heron Therapeutics (HRTX), Organigram Global (OGI), Aardvark Therapeutics (AARD), Innate Pharma (IPHA), Lyell Immunopharma (LYEL), and Cognition Therapeutics (CGTX). These companies are all part of the "pharmaceutical products" industry.
PDS Biotechnology vs. Its Competitors
enGene (NASDAQ:ENGN) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings.
enGene has a beta of -0.41, suggesting that its stock price is 141% less volatile than the S&P 500. Comparatively, PDS Biotechnology has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500.
64.2% of enGene shares are held by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are held by institutional investors. 10.4% of enGene shares are held by insiders. Comparatively, 9.2% of PDS Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
enGene's return on equity of -32.60% beat PDS Biotechnology's return on equity.
enGene presently has a consensus target price of $23.29, suggesting a potential upside of 390.23%. PDS Biotechnology has a consensus target price of $10.00, suggesting a potential upside of 706.45%. Given PDS Biotechnology's higher possible upside, analysts plainly believe PDS Biotechnology is more favorable than enGene.
enGene is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.
In the previous week, enGene had 16 more articles in the media than PDS Biotechnology. MarketBeat recorded 22 mentions for enGene and 6 mentions for PDS Biotechnology. PDS Biotechnology's average media sentiment score of 0.55 beat enGene's score of -0.05 indicating that PDS Biotechnology is being referred to more favorably in the news media.
Summary
enGene beats PDS Biotechnology on 7 of the 13 factors compared between the two stocks.
Get PDS Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for PDSB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PDSB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PDS Biotechnology Competitors List
Related Companies and Tools
This page (NASDAQ:PDSB) was last updated on 8/28/2025 by MarketBeat.com Staff
MarketBeat All Access